AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

REBOA in Nontraumatic OHCA

RecruitingNAAges 20 Years - 80 YearsAllSeoul National University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The investigators propose a multicenter randomized controlled trial in South Korea and Taiwan to observe the clinical effects of REBOA on nontraumatic out-of-hospital-cardiac-arrest (OHCA) patients. While REBOA has been traditionally used in trauma for hemorrhage control, it has also shown promising results in nontraumatic cardiac arrests by rerouting circulation to increase perfusion in the coronary and brain.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Adult nontraumatic OHCA * Witnessed arrest * Arrival at ER from 9AM to 5PM (in South Korea) and 8AM to 8PM (in Taiwan) Exclusion Criteria: 1. age below 20 years old or over 80 years old, 2. traumatic cardiac arrest, 3. those with unwitnessed cardiac arrest, 4. pregnant patients, 5. patients who have already achieved ROSC upon arrival at the emergency department 6. pre-cardiac arrest cerebral performance category of 3-4 7. those showing evidence of cardiac arrest due to bleeding (such as gastrointestinal bleeding) 8. those suspected of having aortic disease, such as dissection, intramural hematoma, or aneurysm, by bedside ultrasound performed immediately after ED arrival or have a previous history of aortic disease 9. whose legal representative has requested termination of resuscitation efforts before study enrollment 10. declared dead at scene before randomization 11. Patients who meet the criteria for extracorporeal cardiopulmonary resuscitation (ECPR), and therefore the decision is made to perform ECPR, will not be enrolled. The ECPR criteria applies when all of the following criteria are met: pre-cardiac arrest CPC of 1-2, witnessed cardiac arrest with bystander CPR, ages between 20-70, initial shockable rhythm, ECMO pump-on available within 60 minutes of onset of cardiac arrest, and patients without end-stage diseases such as cancer, liver cirrhosis, or end-stage renal failure.
๐Ÿ’Š

What it tests

  • REBOA
๐Ÿ“

Where

1 site
Seoul National Univeristy Bundang Hospital
Seongnam-si, South Korea
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy